Eicosatetraenoic acid.

Twenty-carbon fatty acids with four double bonds sit at a branch point in long-chain polyunsaturated metabolism, with the omega-3 form converting onward to EPA and the omega-6 form being arachidonic acid. Which direction the pool goes depends on the enzyme set present and on the ratio of omega-3 to omega-6 substrate arriving. Supplying EPA directly bypasses that conversion entirely. Anyone taking a 20:4 preparation should know which isomer they have, because the two ends of that pathway behave very differently.

GLA is elongated to dihomo-gamma-linolenic acid, and delta-5 desaturase then converts DGLA to arachidonic acid, the omega-6 20:4 fatty acid. That conversion step is the reason GLA supplementation can raise arachidonic acid in some people rather than only raising DGLA. How much converts depends on individual delta-5 desaturase activity. This is the single most important thing to understand before combining GLA with any 20:4 material.

Linoleic acid and alpha-linolenic acid compete for the same desaturase and elongase enzymes, so a high linoleic intake tips the resulting long-chain pool toward omega-6 products. Recent work has examined how dietary linoleic acid intake relates to EPA status and to lipoxygenase-mediated oxylipin formation in people. That competition is a mechanism, and the observational parts of that work describe association rather than cause. Lowering background linoleic acid is a lever on the pool that is independent of what is supplemented.

EPA and DHA displace arachidonic acid from membrane phospholipids and compete with it at cyclooxygenase and lipoxygenase, changing which oxylipins are produced. Controlled infusion work in dairy cattle showed DHA raising circulating pro-resolving oxylipins, and human meta-analyses of omega-3 report effects on outcome measures in specific populations. The direction of the substrate competition is well established; the size of the shift depends on dose and duration. Note that the cattle data are non-human and the human meta-analysis addressed omega-3 rather than the 20:4 species itself.

DHA has a high affinity for membrane phospholipid positions that arachidonic acid also occupies, so raising DHA intake lowers the arachidonic fraction of the membrane over weeks. The consequence is a shift in which oxylipins are generated when those membranes are stimulated. This is displacement, not blockade. The turnover is slow enough that short trials often fail to detect it.

Each additional double bond raises a fatty acid's susceptibility to peroxidation roughly geometrically, so a 20:4 species needs antioxidant protection in any oil it is supplied in. Alpha-tocopherol breaks the peroxidation chain within the lipid phase. This is why every polyunsaturated oil product carries tocopherol. It protects the material rather than changing its biology.

When tocopherol quenches a lipid peroxyl radical it becomes a tocopheroxyl radical, and ascorbate reduces it back to the active form. That recycling extends the protective capacity of a given amount of vitamin E in a polyunsaturated system. The relationship is settled redox chemistry that applies to any highly unsaturated fatty acid. It is about protecting the lipid pool, not about any signalling effect.

Delta-6 and delta-5 desaturase activity depends on adequate zinc status, which is why low zinc is associated with impaired conversion of dietary linoleic and alpha-linolenic acid into their long-chain products. That makes zinc status one determinant of how much 20:4 the body makes from precursors. It has no effect on a preformed 20:4 dose. The cofactor role is established; the practical size of the effect at ordinary zinc intakes is not well quantified.

Pyridoxine is one of the micronutrients required for normal desaturase function in long-chain polyunsaturated fatty acid synthesis, alongside zinc and magnesium. Deficiency slows the conversion of dietary precursors to 20-carbon products. This matters for the endogenous route only. Supplying B6 does not change the fate of a preformed fatty acid.

Chain elongation and desaturation both depend on magnesium-requiring enzymatic steps, so magnesium status is one input into how efficiently short-chain dietary fats are converted to 20-carbon species. It is one of several cofactors and not a rate-setting one on its own. The relationship is textbook, not the subject of dedicated trials. It applies to synthesis, not to preformed intake.

Curcumin has documented inhibitory activity at COX-2 and 5-LOX, the enzymes that convert arachidonic acid into prostaglandins and leukotrienes. That changes what happens to a 20:4 pool without changing the size of the pool. The combination is therefore a modulation of downstream flux rather than an additive supply effect. Bioavailability of oral curcumin is the limiting factor for whether any of this is relevant in practice.

Astaxanthin sits across the lipid bilayer with its polar ends at both membrane surfaces, which lets it quench radicals throughout the membrane rather than only at one face. That geometry suits protection of highly unsaturated fatty acids embedded in the same membrane. It is a stability and protection relationship. No claim about the oxylipin pathway itself is implied.

Glutathione peroxidase 4 is selenium-dependent and specifically reduces phospholipid hydroperoxides in membranes, which is the damage that highly unsaturated fatty acids are prone to. Selenium status therefore sets part of the capacity to handle a high polyunsaturated load. Prepartum selenium supplementation has been shown to shift plasma oxylipin profiles in cattle, which is a non-human result. The enzymatic relationship itself is established human biochemistry.